Search - tctmd.com

Displaying 481 - 500 of 576

Sort: Relevancy | Date

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

News Daily News

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Yael L. Maxwell

March 01, 2018

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

News Daily News

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Michael O'Riordan

February 20, 2018

Impella Heart Pumps Get Expanded Indication for Cardiogenic Shock in Setting of Cardiomyopathy

News Daily News

Impella Heart Pumps Get Expanded Indication for Cardiogenic Shock in Setting of Cardiomyopathy

February 13, 2018

Tool Predicts Stroke Risk in Patients With Systolic Dysfunction After MI

News Daily News

Tool Predicts Stroke Risk in Patients With Systolic Dysfunction After MI

February 12, 2018

Surprising Rate of Cardiac Amyloidosis in TAVR Patients Poses Tough Questions for Diagnosis, Decision-Making

News Daily News

Surprising Rate of Cardiac Amyloidosis in TAVR Patients Poses Tough Questions for Diagnosis, Decision-Making

Michael O'Riordan

February 01, 2018

TCTMD’s Top 10 Most Popular Stories for January 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for January 2018

January 31, 2018

Exercise Study Hints at Volume, Intensity Levels Needed to Improve Cardiac Fitness in Middle Age

News Daily News

Exercise Study Hints at Volume, Intensity Levels Needed to Improve Cardiac Fitness in Middle Age

January 10, 2018

Methamphetamine Use Growing More Common in Veterans With Heart Failure

News Conference News AHA 2017

Methamphetamine Use Growing More Common in Veterans With Heart Failure

November 24, 2017

State-of-the-Art: Latest Innovations in Durable LVADs

Presentation TCT 2017

State-of-the-Art: Latest Innovations in Durable LVADs

Presenter: Ulrich P. Jorde, Michael Mooney, Hiroo Takayama, Nir Uriel

November 01, 2017

Are LV Volumes and Remodeling Suitable Endpoints for Heart Failure Drug and Device Trials?

Presentation TCT 2017

Are LV Volumes and Remodeling Suitable Endpoints for Heart Failure Drug and Device Trials?

Presenter: James E. Udelson

November 01, 2017

Editorial Perspective: The Evolving Role of LVAD in Interventional HF

Presentation TCT 2017

Editorial Perspective: The Evolving Role of LVAD in Interventional HF

Presenter: Louis A. Cannon, Peter J. Fitzgerald, Juan F. Granada, Ileana L. Pina

October 31, 2017

The Hemodynamics of Diastology, LVOT Obstruction, and Exercise Physiology in HCM

Presentation TCT 2017

The Hemodynamics of Diastology, LVOT Obstruction, and Exercise Physiology in HCM

Presenter: Morton J. Kern, Sherif F. Nagueh

October 30, 2017

FDA Grants HeartWare LVAD a Destination Therapy Indication

News Daily News

FDA Grants HeartWare LVAD a Destination Therapy Indication

September 28, 2017

News Industry News

Fewer Leads, Fewer Complications: BIOTRONIK US Launches Proven DX Technology for Heart Failure Patients

July 20, 2017

Cardiac Recovery Possible in Patients With Cardiomyopathy Related to Methamphetamine Abuse

News Daily News

Cardiac Recovery Possible in Patients With Cardiomyopathy Related to Methamphetamine Abuse

May 30, 2017

News Daily News

HeartMate II Left Ventricular Assist System Under Recall Due to Controller Exchange Problems

May 24, 2017

Anabolic Steroid Use Linked With Myocardial Dysfunction and Accelerated Atherosclerosis

News Daily News

Anabolic Steroid Use Linked With Myocardial Dysfunction and Accelerated Atherosclerosis

Alison Palkhivala

May 23, 2017

Manuscript

A Paradox between LV Mass Regression and Hemodynamic Improvement after Surgical and Transcatheter Aortic Valve Replacement

May 09, 2017

Mixed Results, With Some Promising Data, in Heart Failure Destination Therapy Trial

News Conference News

Mixed Results, With Some Promising Data, in Heart Failure Destination Therapy Trial

April 07, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.